Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Digumarthy

MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient With Acquired RET Rearrangement

Journal of Thoracic Oncology

English

P1.04-21 the Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Related publications

BLU-667 Targets RET-Altered Cancers

Cancer Discovery

Oncology

2018

English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology

English

TBC1D32-RET: A Novel RET Oncogenic Fusion in Lung Adenocarcinoma

Journal of Thoracic Oncology

English

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC

Journal of Thoracic Oncology

English

Discovery of Wt RET and V804M RET Inhibitors: From Hit to Lead

English

C-Ret Molecule in Malignant Melanoma From Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines

PLoS ONE

Multidisciplinary

2010

English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Digumarthy

MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient With Acquired RET Rearrangement

P1.04-21 the Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Related publications

BLU-667 Targets RET-Altered Cancers

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

TBC1D32-RET: A Novel RET Oncogenic Fusion in Lung Adenocarcinoma

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC

Discovery of Wt RET and V804M RET Inhibitors: From Hit to Lead

C-Ret Molecule in Malignant Melanoma From Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression